Chemours Appoints Matthew Conti as Chief Human Resources Officer
'I'm honored to join Chemours at such a pivotal moment in its journey. I look forward to partnering with our teams to build a culture that empowers people, accelerates innovation, and drives sustainable growth,' said Matthew Conti, CHRO at Chemours.
Share
In this role, Conti will lead Chemours' global human resources organization, overseeing talent strategy, organizational development, employee engagement, and culture initiatives. He will play a pivotal role in advancing the company's Pathway to Thrive strategy by aligning human capital priorities with business objectives and fostering a high-performing culture.
'Matthew's appointment comes at a critical time as we continue to evolve our culture and capabilities to meet the demands of our stakeholders and the opportunities ahead,' said Denise Dignam, President and CEO of Chemours. 'His deep expertise in global manufacturing environments and his people-first leadership style will help us build a more agile, values-based and high-performing organization.'
'I'm honored to join Chemours at such a pivotal moment in its journey,' said Conti. 'I look forward to partnering with our teams to build a culture that empowers people, accelerates innovation, and drives sustainable growth.'
Conti brings over two decades of HR leadership experience across global manufacturing, specialty chemicals, and industrial sectors. Most recently, he served as CHRO at Vantage Specialty Chemicals, where he led enterprise-wide transformation initiatives. He has also held senior roles at Ingredion Corporation and Precision Castparts Corporation, where he built scalable talent systems and supported complex global operations.
Conti holds a Bachelor of Arts in Economics from Kalamazoo College and an MBA from the London Business School. He will be based at Chemours' global headquarters in Wilmington, Delaware, and serve as a key member of the Executive Team.
About The Chemours Company
The Chemours Company (NYSE: CC) is a global leader in providing industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and advanced electronics, general industrial, and oil and gas. Through our three businesses – Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials – we deliver application expertise and chemistry-based innovations that solve customers' biggest challenges. Our flagship products are sold under prominent brands such as Opteon™, Freon™, Ti-Pure™, Nafion™, Teflon™, Viton™, and Krytox™. Headquartered in Wilmington, Delaware and listed on the NYSE under the symbol CC, Chemours has approximately 6,000 employees and 28 manufacturing sites and serves approximately 2,500 customers in approximately 110 countries. For more information, visit chemours.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, Company performance or growth, the Company's refreshed corporate strategy all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Matters outside our control, including general economic conditions, geopolitical conditions, changes in laws and regulations in the U.S. or other jurisdictions in which we operate, global health and weather events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the 'Company'), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results. 'In the past quarter, our efforts were centered on driving enrollment for the pivotal Phase 3 trial in early AD, which now includes 76 secured clinical sites across the U.S. and over 400 patients screened to date,' said Maria Maccecchini, Ph.D., President and CEO of Annovis. 'At the same time, we reached other notable milestones, including presenting our latest scientific findings at AAIC 2025 with the largest attendance ever from Annovis team and strengthening our global intellectual property protection by completing the transfer of all patent families to crystal buntanetap. As we move forward, our focus stays firmly on completing enrollment as planned to produce strong and trustworthy results, while also advancing our Parkinson's program, with more updates coming as we progress.' Clinical highlights Annovis' pivotal Phase 3 study in early AD (NCT06709014) is advancing rapidly, with 76 U.S. sites secured and 46 currently enrolling patients. The remaining sites are expected to begin enrollment shortly. The pivotal Phase 3 trial has attracted strong participation, with 38 patients already receiving buntanetap or placebo and nearly 200 more in screening – a number that continues to grow each day – with screen failure rate being as expected at 50%. Business highlights In April, Annovis welcomed Hui Liu as Director of Biostatistics, who is responsible for maintaining statistical integrity of the data generated by the Company's clinical trials. In June, Annovis hosted a webcast to provide updates on its Phase 3 trial, engaging directly with the audience through a live Q&A session. The recording is available in the Video Library on the Company's website. In July, senior members of Annovis attended AAIC 2025 in Toronto, presenting four scientific posters highlighting advancements in the Alzheimer's Phase 3 study and the pharmacokinetic profile of its lead drug candidate, buntanetap. All posters are available in the Media Library on the Company's website. In August, Annovis announced the successful transfer of all patent families to crystal buntanetap, achieving comprehensive global IP coverage for both the original and new forms of the Company's drug candidate. Financial results Annovis' cash and cash equivalents totaled $17.1 million as of June 30, 2025, compared to $10.6 million as of December 31, 2024. The Company had 19.5 million shares of common stock outstanding as of June 30, 2025. Research and development expenses for the three months ending June 30, 2025, were $5.2 million compared to $5.8 million for the three months ending June 30, 2024. General and administrative expenses for the three months ending June 30, 2025, were $1.1 million compared to $2.0 million for the three months ending June 30, 2024. Annovis reported a $0.32 basic and diluted net loss per common share for the three months ending June 30, 2025, compared to a $0.44 basic and diluted net loss per common share for the three months ending June 30, 2024. About Annovis Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit and follow us on LinkedIn, YouTube, and X. Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at Forward-Looking StatementsThis press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company's SEC filings under 'Risk Factors' in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA Investor Contact:Alexander Morin, Strategic CommunicationsAnnovis Bioir@ (Tables to follow) ANNOVIS BIO, INC. Balance Sheets (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 17,130,286 $ 10,551,916 Prepaid expenses and other current assets 4,324,285 3,373,717 Total assets $ 21,454,571 $ 13,925,633 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 974,311 $ 2,305,974 Accrued expenses 1,830,813 1,575,013 Total current liabilities 2,805,124 3,880,987 Non-current liabilities: Warrant liability 319,000 737,000 Total liabilities 3,124,124 4,617,987 Commitments and contingencies Stockholders' equity: Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding — — Common stock - $0.0001 par value, 70,000,000 shares authorized, 19,486,231 and 14,141,521 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1,948 1,414 Additional paid-in capital 164,935,088 144,155,694 Accumulated deficit (146,606,589 ) (134,849,462 ) Total stockholders' equity 18,330,447 9,307,646 Total liabilities and stockholders' equity $ 21,454,571 $ 13,925,633 ANNOVIS BIO, INC. Statements of Operations (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 5,161,921 $ 5,785,217 $ 10,173,438 $ 12,307,308 General and administrative 1,109,532 1,977,421 2,380,696 3,265,137 Total operating expenses 6,271,453 7,762,638 12,554,134 15,572,445 Operating loss (6,271,453 ) (7,762,638 ) (12,554,134 ) (15,572,445 ) Other income (expense): Interest income 191,395 25,978 379,007 70,146 Other financing costs — (1,346,060 ) — (1,346,060 ) Change in fair value of warrants (140,000 ) 4,062,308 418,000 10,761,000 Total other income, net 51,395 2,742,226 797,007 9,485,086 Net loss $ (6,220,058 ) $ (5,020,412 ) $ (11,757,127 ) $ (6,087,359 ) Net loss per share Basic $ (0.32 ) $ (0.44 ) $ (0.64 ) $ (0.56 ) Diluted $ (0.32 ) $ (0.44 ) $ (0.64 ) $ (1.52 ) Weighted-average number of common shares used in computing net loss per share Basic 19,486,231 11,307,759 18,464,877 10,966,412 Diluted 19,486,231 11,307,759 18,464,877 11,066,265
Business Wire
10 minutes ago
- Business Wire
Ampco-Pittsburgh Corporation (NYSE: AP) Announces Second Quarter 2025 Results
CARNEGIE, Pa.--(BUSINESS WIRE)--Ampco-Pittsburgh Corporation (NYSE: AP) reported net sales of $113.1 million and $217.4 million for the three and six months ended June 30, 2025, compared to $111.0 million and $221.2 million for the three and six months ended June 30, 2024. Higher sales of forged engineered products and favorable foreign exchange translation offset weaker mill roll sales. Air and Liquid Processing sales were in line with prior year levels. The Corporation reported a loss from operations of $3.1 million for the three months ended June 30, 2025, which included $6.8 million in severance, accelerated depreciation and other costs to exit its U.K. cast roll operations, in anticipation of approval of the exit plan by the UES-UK subsidiary board. Income from operations for the six months ended June 30, 2025 was $0.8 million compared to $5.1 million for the six months ended June 30, 2024, with the U.K. exit costs being the primary change. Adjusted EBITDA of $8.0 million for the three months ended June 30, 2025 declined by $2.1 million from the three months ended June 30, 2024 due to lower margins for the Forged and Cast Engineered Products ('FCEP') segment offset by improved profitability for the Air and Liquid Processing ('ALP') segment. Margins for the FCEP segment were adversely affected by higher manufacturing costs relative to base pricing and variable-index surcharges passed through to customers during the quarter, a weaker sales mix and lower manufacturing cost absorption. Profitability improved for the ALP segment primarily due to a better sales mix. Adjusted EBITDA of $16.8 million for the six months ended June 30, 2025 improved by $1.6 million primarily due to improved profitability for the ALP segment. Commenting on the quarter, Ampco-Pittsburgh's CEO, Brett McBrayer, said, 'After a positive Q1, the volatility from the U.S. tariff actions began to impact our results and our order book in Q2. Backlog in the Forged and Cast Engineered Products segment at June 30, 2025 declined 9% from March 31, 2025 as roll customers began a pause of orders to await less uncertainty surrounding tariffs. In response, we reduced roll production. The decision to exit our U.K. cast roll operations was difficult, but the plan is proceeding. Following the exit, we expect earnings to improve by at least $5 million per year. With less uncertainty on trade policy now with the recent E.U. deal, we expect an improved environment in 2026 after our U.K. exit.' Interest expense of $2.8 million and $5.6 million for the three and six months ended June 30, 2025 is comparable to interest expense for the three and six months ended June 30, 2024. Other (expense) income – net for the three and six months ended June 30, 2025 declined when compared to other (expense) income for the three and six months ended June 30, 2024 primarily due to unfavorable foreign exchange movement. The income tax provision for the three and six months ended June 30, 2025 decreased when compared to the income tax provision for the three and six months ended June 30, 2024 driven by the benefit of a reduced statutory income tax rate for one of the Corporation's foreign tax-paying entities. Net loss approximated $7.3 million, or $0.36 per share, and $6.2 million, or $0.31 per share, for the three and six months ended June 30, 2025, respectively, and includes the $6.8 million charge, or $0.34 per share, for costs associated with exiting the U.K. cast roll operations and a benefit of approximately $0.7 million, or $0.04 per share, for employee-retention credits, representing refundable employer payroll taxes from the Internal Revenue Service for certain eligible businesses affected by the COVID-19 pandemic. This compares to net income of approximately $2.0 million, or $0.10 per share, and a net loss of $0.7 million, or $0.04 per share, for the three and six months ended June 30, 2024, respectively. Teleconference Access Ampco-Pittsburgh Corporation (NYSE: AP) will hold a conference call on Wednesday, August 13, 2025, at 10:30 a.m. Eastern Time (ET) to discuss its financial results for the second quarter ended June 30, 2025. The Corporation encourage participants to pre-register for the conference call using the following link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. To pre-register, please go to Those without internet access or unable to pre-register may dial in by calling: Participant Dial-in (Toll Free): 1-844-308-3408 Participant International Dial-in: 1-412-317-5408 For those unable to listen to the live broadcast, a replay will become available on our website under the Investors menu at About Ampco-Pittsburgh Corporation Ampco-Pittsburgh Corporation manufactures and sells highly engineered, high-performance specialty metal products and customized equipment utilized by industry throughout the world. Through its operating subsidiary, Union Electric Steel Corporation, it is a leading producer of forged and cast rolls for the global steel and aluminum industries. It also manufactures open-die forged products that are sold principally to customers in the steel distribution market, oil and gas industry, and the aluminum and plastic extrusion industries. The Corporation is also a producer of air and liquid processing equipment, primarily custom-engineered finned tube heat exchange coils, large custom air handling systems and centrifugal pumps. It operates manufacturing facilities in the United States, England, Sweden, and Slovenia and participates in three operating joint ventures located in China. It has sales offices in North America, Asia, Europe, and the Middle East. Corporate headquarters is located in Carnegie, Pennsylvania. FORWARD-LOOKING STATEMENTS The Private Securities Litigation Reform Act of 1995 (the 'Act') provides a safe harbor for forward-looking statements made by us or on behalf of Ampco-Pittsburgh Corporation and its subsidiaries (collectively, 'we,' 'us,' 'our,' or the 'Corporation'). This press release may include, but is not limited to, statements about operating performance, trends and events we expect or anticipate will occur in the future, statements about sales and production levels, timing of orders for our products, restructurings, the impact from pandemics and geopolitical conflicts, profitability and anticipated expenses, inflation, the global supply chain, tariffs and global trade, future proceeds from the exercise of outstanding warrants, and cash outflows. All statements in this document other than statements of historical fact are statements that are, or could be, deemed 'forward-looking statements' within the meaning of the Act and words such as 'may,' 'will,' 'intend,' 'believe,' 'expect,' 'anticipate,' 'estimate, 'project,' 'target,' 'goal,' 'forecast' and other terms of similar meaning that indicate future events and trends are also generally intended to identify forward-looking statements. Forward-looking statements speak only as of the date on which such statements are made, are not guarantees of future performance or expectations, and involve risks and uncertainties. For us, these risks and uncertainties include, but are not limited to: inability to maintain adequate liquidity to meet our operating cash flow requirements, repay maturing debt and meet other financial obligations including severance costs associated with our anticipated exit from our operations in the U.K.; economic downturns, cyclical demand for our products and insufficient demand for our products; excess global capacity in the steel industry; inability to successfully restructure our operations, exit our U.K. operations, and/or invest in operations that will yield the best long-term value to our shareholders; liability of our subsidiaries for claims alleging personal injury from exposure to asbestos-containing components historically used in certain products of our subsidiaries; inability to obtain necessary capital or financing on satisfactory terms to acquire capital expenditures that may be necessary to support our growth strategy; inoperability of certain equipment on which we rely; increases in commodity prices or insufficient hedging against increases in commodity prices, reductions in electricity and natural gas supply or shortages of key production materials for us or our customers; inability to satisfy the continued listing requirements of the New York Stock Exchange; potential attacks on information technology infrastructure and other cyber-based business disruptions; fluctuations in the value of the U.S. dollar relative to other currencies; changes in the existing regulatory environment; consequences of pandemics and geopolitical conflicts; work stoppage or another industrial action on the part of any of our unions; failure to maintain an effective system of internal control; changes in the global economic environment, inflation, the ongoing impact of tariffs, elevated interest rates, recessions or prolonged periods of slow economic growth, and global instability and actual and threatened geopolitical conflict; and those discussed more fully elsewhere in Item 1A, Risk Factors, in Part I of the Corporation's latest Annual Report on Form 10-K and Part II of the latest Quarterly Report on Form 10-Q. We cannot guarantee any future results, levels of activity, performance or achievements. In addition, there may be events in the future that we are not able to predict accurately or control which may cause actual results to differ materially from expectations expressed or implied by forward-looking statements. Except as required by applicable law, we assume no obligation, and disclaim any obligation, to update forward-looking statements whether as a result of new information, events or otherwise. NON-GAAP FINANCIAL MEASURES The Corporation presents non-GAAP adjusted EBITDA and non-GAAP adjusted income (loss) from operations. Non-GAAP adjusted EBITDA is calculated as net (loss) income excluding interest expense, other income - net, income tax provision, depreciation and amortization, and stock-based compensation along with significant charges or credits that are one-time charges or credits, unrelated to the Corporation's ongoing results of operations, or beyond its control. Non-GAAP adjusted income (loss) from operations is calculated as income (loss) from operations excluding depreciation and amortization and stock-based compensation along with significant charges or credits that are one-time charges or credits, unrelated to the segment's ongoing results of operations, or beyond its control. During the three and six months ended June 30, 2025, the non-GAAP financial measures were adjusted to exclude severance and other exit costs associated with our anticipated exit from operations in the U.K. and employee-retention credits received in the quarter. These non-GAAP financial measures are not based on any standardized methodology prescribed by accounting principles generally accepted in the United States of America ('GAAP'). Beginning in 2025, the Corporation began presenting non-GAAP adjusted EBITDA along with non-GAAP adjusted income (loss) from operations. These measures are key measures used by the Corporation's management and Board of Directors to understand and evaluate the operating performance of the Corporation and its segments. While these non-GAAP measures may not be directly comparable to similarly titled measures presented by other companies, the Corporation's management and Board of Directors believe these non-GAAP measures enhance comparability to companies in its stated industry peer group. The Corporation believes these non-GAAP financial measures help identify underlying trends in its business that otherwise could be masked by the effect of the items it excludes from adjusted EBITDA and adjusted income (loss) from operations. The Corporation also believes these non-GAAP financial measures provide useful information to management, shareholders and investors, and others in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects and allowing for greater transparency with respect to key financial metrics used by the Corporation's management in its financial and operational decision-making. In particular, the Corporation believes the exclusion of the severance and other exit costs and the employee-retention credits can provide a useful measure for period-to-period comparisons of the Corporation's core business performance. Non-GAAP adjusted EBITDA and non-GAAP adjusted income (loss) from operations are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are limitations related to the use of non-GAAP adjusted EBITDA, rather than net (loss) income, or non-GAAP adjusted income (loss) from operations, rather than (loss) income from operations, which are the nearest GAAP equivalents. Among other things, there can be no assurance that additional expenses similar to the severance and other exit costs or additional benefits similar to the employee-retention credits will not occur in future periods. AMPCO-PITTSBURGH CORPORATION NON-GAAP FINANCIAL MEASURES RECONCILIATION SCHEDULE (in thousands, except percentages) As described under 'Non-GAAP Financial Measures' above, the Corporation presents non-GAAP adjusted EBITDA and non-GAAP adjusted income (loss) from operations as supplemental financial measures to GAAP financial measures. The following is a reconciliation of net (loss) income, the most directly comparable GAAP financial measure, to non-GAAP adjusted EBITDA for the three and six months ended June 30, 2025, and 2024, respectively: Three months ended Six months ended June 30, June 30, 2025 2024 2025 2024 Net (loss) income (GAAP) $ (6,720 ) $ 2,552 $ (4,829 ) $ 346 Add (deduct): Interest expense 2,825 3,017 5,551 5,774 Other loss (income) – net 225 (1,389 ) (601 ) (2,312 ) Income tax provision 592 863 651 1,317 (Loss) income from operations (3,078 ) 5,043 772 5,125 Add: Depreciation and amortization (1) 5,368 4,698 10,004 9,368 Severance and other exit costs 6,096 - 6,096 - Employee-retention credits (735 ) - (735 ) - Stock-based compensation 332 388 638 734 EBITDA, as adjusted (Non-GAAP) $ 7,983 $ 10,129 $ 16,775 $ 15,227 Net sales $ 113,104 $ 110,988 $ 217,369 $ 221,203 Adjusted EBITDA margin 7.06 % 9.13 % 7.72 % 6.88 % (1) Depreciation and amortization expense for the three and six months ended June 30, 2025 includes accelerated depreciation of $654 associated with exiting the U.K. operations. Expand AMPCO-PITTSBURGH CORPORATION NON-GAAP FINANCIAL MEASURES RECONCILIATION SCHEDULE, CONTINUED (in thousands, except percentages) The following is a reconciliation of (loss) income from operations, the most directly comparable GAAP financial measure, to non-GAAP adjusted (loss) income from operations for the three and six months ended June 30, 2025, and 2024, respectively: Three months ended June 30, 2025 2024 FCEP ALP Corporate (1) Ampco Consolidated FCEP ALP Corporate (1) Ampco Consolidated (Loss) income from operations $ (3,963 ) $ 3,922 $ (3,037 ) $ (3,078 ) $ 5,361 $ 3,174 $ (3,492 ) $ 5,043 Add: Depreciation and amortization (2) 5,084 284 - 5,368 4,454 244 - 4,698 Severance and other exit costs 6,096 - - 6,096 - - - - Employee-retention credits (456 ) (279 ) - (735 ) - - - - Stock-based compensation - - 332 332 - - 388 388 Income (loss) from operations, as adjusted (Non-GAAP) $ 6,761 $ 3,927 $ (2,705 ) $ 7,983 $ 9,815 $ 3,418 $ (3,104 ) $ 10,129 Net sales $ 77,909 $ 35,195 $ 113,104 $ 75,713 $ 35,275 $ 110,988 Six months ended June 30, 2025 2024 FCEP ALP Corporate (1) Ampco Consolidated FCEP ALP Corporate (1) Ampco Consolidated (Loss) income from operations $ (58 ) $ 7,416 $ (6,586 ) $ 772 $ 6,937 $ 5,156 $ (6,968 ) $ 5,125 Add: Depreciation and amortization (2) 9,452 552 - 10,004 8,884 484 - 9,368 Severance and other exit costs 6,096 - - 6,096 - - - - Employee retention credits (456 ) (279 ) - (735 ) - - - - Stock-based compensation - - 638 638 - - 734 734 Income (loss) from operations, as adjusted (Non-GAAP) $ 15,034 $ 7,689 $ (5,948 ) $ 16,775 $ 15,821 $ 5,640 $ (6,234 ) $ 15,227 Net sales $ 150,196 $ 67,173 $ 217,369 $ 152,902 $ 68,301 $ 221,203 Adjusted margin from operations 10.01 % 11.45 % 7.72 % 10.35 % 8.26 % 6.88 % (1) Corporate represents the operating expenses of the corporate office and other costs not allocated to the segments. (2) Depreciation and amortization expense for the three and six months ended June 30, 2025 includes accelerated depreciation of $654 associated with exiting the U.K. operations. Expand
Business Wire
10 minutes ago
- Business Wire
The Toro Company Names Edric C. Funk President and Chief Operating Officer
BLOOMINGTON, Minn.--(BUSINESS WIRE)--The Toro Company (NYSE: TTC), a leading global provider of solutions for the outdoor environment, today announced that Edric C. Funk has been appointed president and chief operating officer, effective September 1, 2025. Funk, a 29-year veteran of the company, has served as group vice president of Golf, Grounds and Irrigation since 2022. In this new role, he will assume responsibility for all of the company's global businesses and integrated supply chain operations, continuing to report to Richard M. Olson, chairman and chief executive officer. 'Edric's track record of driving business performance and fostering innovation uniquely equips him for the role of chief operating officer,' said Olson. 'Throughout his tenure, Edric has consistently delivered strong financial results and value creation across diverse technical and business functions – directly contributing to our growth and competitive position. His deep understanding of our customers, and technologies coupled with a disciplined strategic approach, will continue to propel The Toro Company forward and create value for all stakeholders.' Since joining The Toro Company in 1996 as a design engineer, Funk transitioned to marketing in 2003 and held roles of increasing responsibility in the company's Residential, Landscape Contractor, International and Commercial businesses. In 2014, he was promoted to director of global product management for the Commercial and International businesses, and in 2017 was named managing director of the company's Center for Technology, Research & Innovation (CTRI). Funk went on to become the general manager of the Sitework Systems business in 2020, before being promoted to group vice present of Golf, Grounds and Irrigation, where he has played an influential role in driving performance across multiple professional product categories. Funk was instrumental in the acquisitions of both Left Hand Robotics and TURFLYNX, which accelerated the development of robotic mowing platforms recently introduced to the market. He also elevated the organization's technology community through the creation of its Technology Forum and has championed integrated smart systems delivering more holistic solutions for customers. In 2020, he was recognized by Golf, Inc. as one of the Most Innovative People in Golf. 'I am honored to serve in this role, and I look forward to working alongside our talented team to drive operational performance across our businesses, with a focus on accelerating profitable growth, advancing the company's technology roadmap and optimizing global supply chain operations,' said Funk. Funk received a Bachelor of Science in engineering from the University of Minnesota and an MBA from The University of Minnesota – Carlson School of Management. He also has a professional certificate in innovation and technology from the Massachusetts Institute of Technology. He serves on the boards of the National Golf Foundation, The Toro Company Foundation, and Red Iron Acceptance. About The Toro Company The Toro Company (NYSE: TTC) is a leading global provider of solutions for the outdoor environment including turf and landscape maintenance, snow and ice management, underground utility construction, rental and specialty construction, and irrigation and outdoor lighting solutions. With net sales of $4.6 billion in fiscal 2024, The Toro Company's global presence extends to more than 125 countries through a family of brands that includes Toro, Ditch Witch, Exmark, Spartan, BOSS, Ventrac, American Augers, Subsite, HammerHead, Radius, Perrot, Hayter, Unique Lighting Systems, Irritrol, and Lawn-Boy. Through constant innovation and caring relationships built on trust and integrity, The Toro Company and its family of brands have built a legacy of excellence by helping customers work on golf courses, sports fields, construction sites, public green spaces, commercial and residential properties and agricultural operations. For more information, visit
